Skip to main content

Table 4 Change in parameters between baseline and 6-months follow-up. Change in parameters that are associated with JIA (paediatric rheumatologist) and uveitis (ophthalmologist) and patient reported outcome measures from baseline to 6-months follow-up (bold highlighted beta/ OR were statistically significant)

From: Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)

 Baseline3-months follow-up6-months follow-upChange between Baseline and 3-months follow-upChange between Baseline and 6-months follow-upChange between 3-months and 6-months follow-upEffect Size
Baseline to 6-months follow-up
n; mean (sd), mediann; mean (sd), mediann; mean (sd), medianbeta/ OR p value 95% CIbeta/ OR p value 95% CIbeta/ OR p value 95% CI
n(%)an(%)an(%)a    
 Analyses on patient level    
 n = 82n = 77n = 64    
Pediatric rheumatologist
 Physician’s global about JIA disease activity, VAS, 0–10071; 34.0 (28.7); 3064; 17.0 (22.6); 1057; 13.4 (22.4); 5−17.7 < 0.001–23.29; −12.14−20.2 < 0.001–26.09; −14.41−2.5 0.401–8.46; 3.380.66
 Number of joints with active arthritis83; 0.6 (1.5); 077; 0.4 (1.5); 064; 0.9 (3.8); 0−0.1 0.636–0.77; 0.470.3 0.313–0.32; 1.000.5 0.152–0.18; 1.150.10
Patients reported outcomes
 Overall well-being; VAS; 0–10047; 34.1 (29.7); 2643; 23.5 (20.3); 2030; 23.2 (22.3); 12−10.5 0.003–17.48; −3.62−13.1 0.001–20.93; −5.27− 2.6 0.524–10.39; 5.290.41
 C-HAQ, 0–335; 0.81 (1.04); 0.527; 0.69 (0.88); 0.518; 0.52 (0.59); 0.44− 0.2 0.056–0.45; 0.01− 0.3 0.014–0.61; − 0.07−0.1 0.4–0.39; 0.160.13
 PedsQL, 0–10052; 78.7 (21.5); 87.840; 81.7 (17.9); 86.926; 85.5 (13.5); 89.73.8 0.088–0.57; 8.217.2 0.006 2.08; 12.303.4 0.201–1.80; 8.540.15
 Number of days in hospital due to uveitis40; 1.9 (6.0); 032; 0.7 (2.7); 019; 1.1 (4.2); 0−1.2 0.274–3.33; 0.94−0.7 0.561–3.26; 1.770.4 0.736–2.16; 3.060.25
 Missed days in kindergarden/ school due to uveitis51; 4.8 (6.7); 147; 3.2 (9.2); 032; 0.5 (1.6); 0−1.7 0.211–4.30; 0.95−4.3 0.004–7.25; − 1.34−2.6 0.085–5.61; 0.370.20
 Number of days with restrictions in daily life due to uveitis39; 7.4 (16.9); 032; 1.7 (4.8); 019; 5.0 (10.6); 0−5.9 0.037–11.40; − 0.36−2.7 0.417–9.25; 3.833.2 0.355–3.55; 9.900.44
 Analyses on eye level    
 n = 147n = 132n = 103    
Ophthalmologist
 Physician’s global about disease activity in the eyes, VAS, 0–100113; 45.2 (33.9); 50111; 30.6 (33.5); 2087; 25.2 (32.3); 14−15.0 < 0.001–19.13; − 10.83−20.0 < 0.001–24.57; − 15.44− 5.0 0.029–9.55; − 0.510.43
 Total number of AC cells46; 7.4 (6.4); 7.528; 1.4 (3.2); 033; 1.9 (4.8); 0−4.9 < 0.001–6.99; − 2.79− 5.0 < 0.001–7.03; − 2.91−0.1 0.942–2.29; 2.121.10
 Visual acuity, logMAR119; 0.48 (0.51); 0.3101; 0.39 (0.50); 0.186; 0.42 (0.52); 0.11−0.1 0.015–0.11; − 0.01−0.1 0.062–0.10; 0.000.0 0.727–0.04; 0.060.18
 AC cell grade136; 2.81 (1.25); 3116; 1.81 (1.20); 193; 1.39 (0.82); 1−1.0 < 0.001–1.26; − 0.80−1.5 < 0.001–1.72; − 1.22−0.4 0.001–0.69; − 0.190.81
 AC flare grade (no flare versus flare), SUN99 (70.2%)49 (38.6%)24 (25.3%)0.1 < 0.001 0.03; 0.210.0 < 0.001 0.01; 0.080.3 0.006 0.12; 0.710.67
 AC flare grade (no flare versus flare), MIWGUC53 (61.6%)31 (37.4%)17 (25.8%)0.1 < 0.001 0.03; 0.340.0 < 0.001 0.01; 0.140.3 0.032 0.09; 0.900.50
 Any structural complications81 (56.3%)73 (56.2%)64 (62.1%)0.9 0.867 0.27; 2.991.1 0.904 0.28; 4.281.2 0.79 0.30; 4.770.01
 Ocular hypotony3 (2.1%)3 (2.4%)0 (0.0%)bbb0.02
 Ocular hypertension6 (4.3%)8 (6.5%)4 (4.1%)6.2 0.235 0.31; 124.320.2 0.321 0.01; 4.050.0 0.109 0.00; 2.060.09
 Posterior synechiae60 (43.2%)60 (46.2%)53 (52.0%)5.7 0.23 0.33; 96.674.7 0.324 0.21; 104.420.8 0.903 0.05; 15.330.06
 Glaucoma6 (4.4%)6 (5.1%)5 (5.4%)bbb0.03
 Cataract28 (19.9%)23 (18.3%)24 (23.5%)bbb0.04
 Band keratopathy31 (21.5%)31 (24.6%)27 (26.7%)25.6 0.067 0.80; 826.7514.8 0.132 0.44; 493.900.6 0.716 0.03; 11.130.07
 Optic disc edema10 (10.9%)6 (7.0%)3 (4.8%)bbb0.11
 Macular edema (Funduscopy)9 (7.0%)4 (5.0%)2 (2.9%)0.3 0.288 0.04; 2.680.2 0.195 0.02; 2.140.7 0.811 0.06; 9.420.07
 Macular edema (OCT)14 (21.5%)4 (12.5%)2 (6.1%)bbb0.08
 Epiretinal membrane formation (Funduscopy)7 (5.5%)7 (8.5%)4 (5.9%)bbb0.12
 Epiretinal membrane formation (OCT)7 (11.3%)7 (17.5%)5 (14.3%)bbb0.11
 Vitreous haze (yes/no)15 (16.3%)15 (18.3%)13 (19.1%)1.6 0.518 0.38; 6.971.5 0.632 0.31; 6.750.9 0.89 0.20; 4.110.06
 Other complications12 (12.8%)2 (2.4%)0 (0.0%)bbb0.10
  1. beta regression coefficient for continuously distributed variables, CI confidence interval, n number of patients with valid assessment in the reported parameter, OR Odds ratio for categorical variables, sd standard deviation
  2. apercentages refer to the number of patients or eyes with valid assessments in the considered parameter
  3. bnot estimable due to the low number of complications